Am J Psychiatry 159:180-190, February 2002
© 2002 American Psychiatric Association
Amisulpride, an Unusual "Atypical" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Stefan Leucht, M.D.,
Gabi Pitschel-Walz, Ph.D.,
Rolf R. Engel, Ph.D., and
Werner Kissling, M.D.
OBJECTIVE: The "atypical" profile of the new antipsychotics clozapine, olanzapine, quetiapine, and risperidone has been linked to combined antagonism of serotonin 2 (5-HT2) and dopamine 2 (D2) receptors. Although amisulpride is a highly selective D3/D2 receptor antagonist, it is assumed to have atypical properties as well. The purpose of this article was to compare the atypical profile of amisulpride with that of the 5-HT2/D2 antagonists. METHOD: Randomized controlled trials that compared amisulpride with conventional antipsychotics or placebo for patients with schizophrenia were identified and included in a meta-analysis. The mean effect sizes found for amisulpride were compared with those of an updated meta-analysis of the 5-HT2/D2 antagonists. RESULTS: Eighteen randomized controlled trials of amisulpride (N=2,214) were found. In 11 studies of acutely ill patients it proved to be consistently more effective than conventional antipsychotics for global schizophrenic symptoms (measured with the Brief Psychiatric Rating Scale) and negative symptoms. Amisulpride is to date the only atypical antipsychotic for which several studies of patients suffering predominantly from negative symptoms have been published. In four such studies amisulpride was significantly more effective than placebo. Three small studies with conventional antipsychotics as comparators showed only a trend in favor of amisulpride in this regard. Amisulpride was associated with clearly lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. CONCLUSIONS: These results cast some doubt on the notion that combined 5-HT2/D2 antagonism is the reason that the newer antipsychotic medications are effective for negative symptoms and have fewer extrapyramidal side effects.
This article has been cited by other articles:
|
|
|
|
 
S. Leucht, S. Heres, J. Hamann, and J. M. Kane
Methodological Issues in Current Antipsychotic Drug Trials
Schizophr Bull,
March 1, 2008;
34(2):
275 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sacchetti, G. Trifiro, A. Caputi, C. Turrina, E. Spina, C. Cricelli, O. Brignoli, E. Sessa, and G. Mazzaglia
Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects
J Psychopharmacol,
January 1, 2008;
22(1):
39 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. A. Gibbs, K. H. Naudts, E. P. Spencer, and A. S. David
The Role of Dopamine in Attentional and Memory Biases for Emotional Information
Am J Psychiatry,
October 1, 2007;
164(10):
1603 - 1609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Tamminga and J. M. Davis
The Neuropharmacology of Psychosis
Schizophr Bull,
July 1, 2007;
33(4):
937 - 946.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Scherk, F. G. Pajonk, and S. Leucht
Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Arch Gen Psychiatry,
April 1, 2007;
64(4):
442 - 455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, R. R. Engel, J. Bauml, and J. M. Davis
Is the Superior Efficacy of New Generation Antipsychotics an Artifact of LOCF?
Schizophr Bull,
January 1, 2007;
33(1):
183 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis
The Choice of Drugs for Schizophrenia
N. Engl. J. Med.,
February 2, 2006;
354(5):
518 - 520.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
Am J Psychiatry,
February 1, 2006;
163(2):
185 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker
Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis
Arch Gen Psychiatry,
December 1, 2005;
62(12):
1305 - 1312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gilles, A. Wilke, D. Kopf, A. Nonell, H. Lehnert, and M. Deuschle
Antagonism of the Serotonin (5-HT)-2 Receptor and Insulin Sensitivity: Implications for Atypical Antipsychotics
Psychosom Med,
September 1, 2005;
67(5):
748 - 751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Correll, S. Leucht, and J. M. Kane
Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Am J Psychiatry,
March 1, 2004;
161(3):
414 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Freedman
Schizophrenia
N. Engl. J. Med.,
October 30, 2003;
349(18):
1738 - 1749.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Bressan, K. Erlandsson, H. M. Jones, R. Mulligan, R. J. Flanagan, P. J. Ell, and L. S. Pilowsky
Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients
Am J Psychiatry,
August 1, 2003;
160(8):
1413 - 1420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry,
June 1, 2003;
60(6):
553 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. Fleischhacker, P. Czobor, M. Hummer, G. Kemmler, R. Kohnen, and J. Volavka
Placebo or Active Control Trials of Antipsychotic Drugs?
Arch Gen Psychiatry,
May 1, 2003;
60(5):
458 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Remington and S. Kapur
Review: amisulpride is effective and safe for schizophrenia
Evid. Based Ment. Health,
August 1, 2002;
5(3):
85 - 85.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
